Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dexmedetomidine vs Nalbuphine as Adjuvants to Intrathecal Bupivacaine
NCT05347173Completed
- Sponsor
- Mansoura University
- Start
- Jun 2022
- Primary completion
- Jan 2024
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
Randomised, double-blind trial of dexmedetomidine and nalbuphine in pain (3 arms), sponsored by Mansoura University. Primary endpoint: Post-operative analgesic duration at 24 hours. Started Jun 2022; status: completed.
02
Drugs
dexmedetomidinenalbuphine
03
Conditions
pain
Beyond the preview
Go deeper on NCT05347173.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05347173.